The approval of anti-bacterial injection, Ertapenem, provides a significant opportunity with limited competition.
Why this is important?
A complex injectable product launch in the US is good news for aurobindo. This anti-bacterial injection is for treatment of complicated skin and skin infections in adult. This will help the company to overcome the pricing pressure going on in the US.
Stock to be impacted?
This is good news for the company alongwith the FDA clearance of unit IV. (CMP 603, M. Cap 35,447 crs, P/BV 3.02)